Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF in Chronic Hepatitis B with Normal ALT
NCT04231565Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jun 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in Chronic Hepatitis B (CHB) comparing TAF Group with Observation Group (2 arms). Primary endpoint: Hepatitis B surface antigen decrease from baseline at 144 weeks. Started Jun 2020; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04231565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231565.